151 related articles for article (PubMed ID: 32328816)
1. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
[TBL] [Abstract][Full Text] [Related]
3. A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
Sambi M; Samuel V; Qorri B; Haq S; Burov SV; Markvicheva E; Harless W; Szewczuk MR
Drug Des Devel Ther; 2020; 14():1995-2019. PubMed ID: 32546966
[TBL] [Abstract][Full Text] [Related]
4. Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro.
Abrahams B; Gerber A; Hiss DC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474312
[TBL] [Abstract][Full Text] [Related]
5. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein.
Abd-Ellatef GEF; Gazzano E; El-Desoky AH; Hamed AR; Kopecka J; Belisario DC; Costamagna C; S Marie MA; Fahmy SR; Abdel-Hamid AZ; Riganti C
Pharmacol Res; 2022 Jan; 175():105975. PubMed ID: 34785319
[TBL] [Abstract][Full Text] [Related]
6. The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.
Wang W; Rana PS; Markovic V; Sossey-Alaoui K
Breast Cancer Res; 2023 Mar; 25(1):31. PubMed ID: 36949468
[TBL] [Abstract][Full Text] [Related]
7. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Smoots SG; Schreiber AR; Jackson MM; Bagby SM; Dominguez ATA; Dus ED; Binns CA; MacBeth M; Whitty PA; Diamond JR; Pitts TM
Breast Cancer Res; 2024 Mar; 26(1):35. PubMed ID: 38429789
[TBL] [Abstract][Full Text] [Related]
8. Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo.
Pateliya B; Burade V; Goswami S
Eur J Pharmacol; 2021 Jan; 891():173725. PubMed ID: 33157041
[TBL] [Abstract][Full Text] [Related]
9. Molecular Modification of Metadherin/MTDH Impacts the Sensitivity of Breast Cancer to Doxorubicin.
Song Z; Wang Y; Li C; Zhang D; Wang X
PLoS One; 2015; 10(5):e0127599. PubMed ID: 25993398
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells.
Lu S; Morris VB; Labhasetwar V
J Pharmacol Exp Ther; 2019 Sep; 370(3):902-910. PubMed ID: 30940690
[TBL] [Abstract][Full Text] [Related]
11. Curcumin Inhibits the PPARδ-p-Akt-GLUT1 Pathway and Ameliorates the Antiproliferative Effects of Doxorubicin in MDA-MB-231 Cells.
Thulasiraman P; Foret M; Pandit R; McAlister K
Asian Pac J Cancer Prev; 2024 Mar; 25(3):1035-1043. PubMed ID: 38546086
[TBL] [Abstract][Full Text] [Related]
12. Integrative transcriptome analysis of triple negative breast cancer profiles for identification of druggable targets.
Arumugam P; Ramesh V; Sampathkumar B; Perumalsamy H; Balusamy SR; Suganya K; Balraj S; Nachimuthu SK; Sundaravadivelu S
J Biomol Struct Dyn; 2023; 41(21):12106-12119. PubMed ID: 36617953
[TBL] [Abstract][Full Text] [Related]
13. Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis.
Liu Q; Song X; Liu Z; Yu Z
Technol Cancer Res Treat; 2021; 20():15330338211019506. PubMed ID: 34184566
[TBL] [Abstract][Full Text] [Related]
14. PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer.
Zhuang F; Huang S; Liu L
Int J Biochem Cell Biol; 2024 Jun; 171():106581. PubMed ID: 38642827
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial dynamics as a novel treatment strategy for triple-negative breast cancer.
Wang Y; Harada-Shoji N; Kitamura N; Yamazaki Y; Ebata A; Amari M; Watanabe M; Miyashita M; Tada H; Abe T; Suzuki T; Gonda K; Ishida T
Cancer Med; 2024 Jan; 13(2):e6987. PubMed ID: 38334464
[TBL] [Abstract][Full Text] [Related]
16. Yttrium Oxide nanoparticles induce cytotoxicity, genotoxicity, apoptosis, and ferroptosis in the human triple-negative breast cancer MDA-MB-231 cells.
Emad B; WalyEldeen AA; Hassan H; Sharaky M; Abdelhamid IA; Ibrahim SA; Mohamed HR
BMC Cancer; 2023 Nov; 23(1):1151. PubMed ID: 38012585
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy application of Abemaciclib with Doxorubicin in triple negative breast cancer cell line MDA-MB-231.
Eralp TN; Sevinc A; Mansuroglu B
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):169-177. PubMed ID: 38430025
[TBL] [Abstract][Full Text] [Related]
18. Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.
Gujrati M; Vaidya AM; Mack M; Snyder D; Malamas A; Lu ZR
Adv Healthc Mater; 2016 Nov; 5(22):2882-2895. PubMed ID: 27723260
[TBL] [Abstract][Full Text] [Related]
19. Multiple suppressing small interfering RNA for cancer treatment-Application to triple-negative breast cancer.
Lee J; Bang JH; Ryu YC; Hwang BH
Biotechnol J; 2023 Nov; 18(11):e2300060. PubMed ID: 37478121
[TBL] [Abstract][Full Text] [Related]
20. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer.
Guo P; Yang J; Jia D; Moses MA; Auguste DT
Theranostics; 2016; 6(1):1-13. PubMed ID: 26722369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
